{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:17:56Z","timestamp":1791386276343,"version":"4.3.3"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Innate immunity, armed with pattern recognition receptors including Toll-like receptors (TLR), is critical for immune cell activation and the connection to anti-microbial adaptive immunity. However, information regarding the impact of age on the innate immunity in response to SARS-CoV2 adenovirus vector vaccines and its association with specific immune responses remains scarce.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Fifteen subjects between 25-35 years (the young group) and five subjects between 60-70 years (the older adult group) were enrolled before ChAdOx1 nCoV-19 (AZD1222) vaccination. We determined activation markers and cytokine production of monocyte, natural killer (NK) cells and B cells <jats:italic>ex vivo<\/jats:italic> stimulated with TLR agonist (poly (I:C) for TLR3; LPS for TLR4; imiquimod for TLR7; CpG for TLR9) before vaccination and 3-5 days after each jab with flow cytometry. Anti-SARS-CoV2 neutralization antibody titers (surrogate virus neutralization tests, sVNTs) were measured using serum collected 2 months after the first jab and one month after full vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The older adult vaccinees had weaker vaccine-induced sVNTs than young vaccinees after 1<jats:sup>st<\/jats:sup> jab (47.2\u00b119.3% vs. 21.2\u00b122.2%, <jats:italic>p<\/jats:italic> value&amp;lt;0.05), but this difference became insignificant after the 2<jats:sup>nd<\/jats:sup> jab. Imiquimod, LPS and CpG strongly induced CD86 expression in IgD<jats:sup>+<\/jats:sup>CD27<jats:sup>-<\/jats:sup> na\u00efve and IgD<jats:sup>-<\/jats:sup>CD27<jats:sup>+<\/jats:sup> memory B cells in the young group. In contrast, only the IgD<jats:sup>+<\/jats:sup> CD27<jats:sup>-<\/jats:sup> na\u00efve B cells responded to these TLR agonists in the older adult group. Imiquimode strongly induced the CD86 expression in CD14<jats:sup>+<\/jats:sup> monocytes in the young group but not in the older adult group. After vaccination, the young group had significantly higher IFN-\u03b3 expression in CD3<jats:sup>-<\/jats:sup> CD56<jats:sup>dim<\/jats:sup> NK cells after the 1<jats:sup>st<\/jats:sup> jab, whilst the older adult group had significantly higher IFN-\u03b3 and granzyme B expression in CD56<jats:sup>bright<\/jats:sup> NK cells after the 2<jats:sup>nd<\/jats:sup> jab (all <jats:italic>p<\/jats:italic> value &amp;lt;0.05). The IFN-\u03b3 expression in CD56<jats:sup>dim<\/jats:sup> and CD56<jats:sup>bright<\/jats:sup> NK cells after the first vaccination and CD86 expression in CD14<jats:sup>+<\/jats:sup> monocyte and IgD<jats:sup>-<\/jats:sup>CD27<jats:sup>-<\/jats:sup>double-negative B cells after LPS and imiquimod stimulation correlated with vaccine-induced antibody responses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The innate immune responses after the first vaccination correlated with the neutralizing antibody production. Older people may have defective innate immune responses by TLR stimulation and weak or delayed innate immune activation profile after vaccination compared with young people.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.807454","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T08:43:42Z","timestamp":1643100222000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination"],"prefix":"10.3389","volume":"13","author":[{"given":"Ching-Fen","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Liang","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Min","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-De","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Hsiung","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tzu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chien","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chang","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"B1","unstructured":"Coronavirus Pandemic (COVID-19)2020"},{"key":"B2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and Efficacy of the ChAdOx1 Ncov-19 Vaccine (AZD1222) Against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaa274","article-title":"Efficacy and Safety of COVID-19 Vaccines in Older People","volume":"50","author":"Soiza","year":"2021","journal-title":"Age Ageing"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and Immunogenicity of ChAdOx1 Ncov-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2\/3 Trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA Vaccines\u2014A New Era in Vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2007.10.005","article-title":"Adenovirus Vector Induced Innate Immune Responses: Impact Upon Efficacy and Toxicity in Gene Therapy and Vaccine Applications","volume":"132","author":"Hartman","year":"2008","journal-title":"Virus Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 Vaccines: Modes of Immune Activation and Future Challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11357-021-00323-3","article-title":"The Impact of Immuno-Aging on SARS-CoV-2 Vaccine Development","volume":"43","author":"Connors","year":"2021","journal-title":"Geroscience"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.579220","article-title":"I Mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People","volume":"11","author":"Pietrobon","year":"2020","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583019","article-title":"Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly","volume":"11","author":"Pereira","year":"2020","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901022","article-title":"Age-Associated Decrease in TLR Function in Primary Human Dendritic Cells Predicts Influenza Vaccine Response","volume":"184","author":"Panda","year":"2010","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 Vaccines Against the B. 1.617. 2 (Delta) Variant","volume":"38","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.14.21267615","article-title":"Effectiveness of COVID-19 Vaccines Against the Omicron (B. 1.1. 529) Variant of Concern","author":"Andrews","year":"2021","journal-title":"MedRxiv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2013.05.014","article-title":"Vaccine Strategies to Enhance Immune Responses in the Aged","volume":"25","author":"Lefebvre","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of High-Dose Versus Standard-Dose Influenza Vaccine in Older Adults","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The History of MF59\u00ae Adjuvant: A Phoenix That Arose From the Ashes","volume":"12","author":"O\u2019Hagan","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.10.016","article-title":"Vaccine Development: From Concept to Early Clinical Testing","volume":"34","author":"Cunningham","year":"2016","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","article-title":"Vaccination in the Elderly: The Challenge of Immune Changes With Aging","volume":"40","author":"Ciabattini","year":"2018","journal-title":"Semin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 Surrogate Virus Neutralization Test Based on Antibody-Mediated Blockage of ACE2-Spike Protein-Protein Interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e23921","DOI":"10.1002\/jcla.23921","article-title":"Performance Evaluation of Three Automated Quantitative Immunoassays and Their Correlation With a Surrogate Virus Neutralization Test in Coronavirus Disease 19 Patients and Pre-Pandemic Controls","volume":"35","author":"Jung","year":"2021","journal-title":"J Clin Lab Anal"},{"key":"B21","doi-asserted-by":"publisher","first-page":"15223","DOI":"10.1038\/s41598-021-94624-4","article-title":"Lower Peripheral Blood Toll-Like Receptor 3 Expression Is Associated With an Unfavorable Outcome in Severe COVID-19 Patients","volume":"11","author":"Menezes","year":"2021","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1010","DOI":"10.1002\/cti2.1010","article-title":"Vaccinating for Natural Killer Cell Effector Functions","volume":"7","author":"Wagstaffe","year":"2018","journal-title":"Clin Transl Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/j.celrep.2019.01.104","article-title":"Influenza Vaccination Induces NK-Cell-Mediated Type-II IFN Response That Regulates Humoral Immunity in an IL-6-Dependent Manner","volume":"26","author":"Farsakoglu","year":"2019","journal-title":"Cell Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00357-07","article-title":"Elevated Frequency of Gamma Interferon-Producing NK Cells in Healthy Adults Vaccinated Against Influenza Virus","volume":"15","author":"Long","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000844","article-title":"NK Cells as Effectors of Acquired Immune Responses: Effector CD4+ T Cell-Dependent Activation of NK Cells Following Vaccination","volume":"185","author":"Horowitz","year":"2010","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.07.004","article-title":"Boosting Vaccine Efficacy the Natural (Killer) Way","volume":"36","author":"Rydyznski","year":"2015","journal-title":"Trends Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.tips.2021.06.004","article-title":"Targeting Natural Killer Cells to Enhance Vaccine Responses","volume":"42","author":"Cox","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.10.6624","article-title":"A New Population of Cells Lacking Expression of CD27 Represents a Notable Component of the B Cell Memory Compartment in Systemic Lupus Erythematosus","volume":"178","author":"Wei","year":"2007","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2009.08.003","article-title":"A Double-Negative (IgD-CD27-) B Cell Population Is Increased in the Peripheral Blood of Elderly People","volume":"130","author":"Colonna-Romano","year":"2009","journal-title":"Mech Ageing Dev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging Concepts in the Science of Vaccine Adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.807454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T08:43:46Z","timestamp":1643100226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.807454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2022.807454"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.807454","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]},"article-number":"807454"}}